NASUS PHARMA ANNOUNCES ENROLLMENT AND DOSING OF FIRST PATIENT IN PHASE 1 STUDY OF NS003 INTRANASAL FORMULATION OF ONDANSETRON

Reuters · 2d ago

Please log in to view news